Arcus Biosciences
Update in progressRCUS (NYSE)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Arcus Biosciences is a clinical-stage biopharmaceutical company in the United States focused on cancer therapies. Its portfolio includes Casdatifan (HIF-2a inhibitor for kidney cancer), Domvanalimab (anti-TIGIT) in Phase 2/3 for lung and GI cancers, and Zimberelimab (anti-PD-1). Quemliclustat targets CD73 in the adenosine pathway; AB598 targets CD39; AB801 inhibits AXL. Collaborations with AstraZeneca for NSCLC and ccRCC trials, and with BVF Partners, support inflammatory disease programs. Founded 2015, Hayward, California.
Company score
- Sentiment
- -0.17
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- -0.17
- Governance
- -0.02
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- -0.05
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- -0.11
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Sort by
Order by
Timeframe
No news articles are available for this company yet.
Unable to load company news.
Loading more news
You're all caught up!